---
title: "Kronos Bio (KRON.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KRON.US.md"
symbol: "KRON.US"
name: "Kronos Bio"
industry: "Biotechnology"
datetime: "2026-03-13T22:21:34.537Z"
locales:
  - [en](https://longbridge.com/en/quote/KRON.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KRON.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KRON.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/KRON.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/KRON.US.md)


# Kronos Bio (KRON.US)

## Company Overview

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren’s disease. The company was incorporated in 2017 and is headquartered in San Mateo, California.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-13T04:30:16.000Z

**Overall: C (0.53)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 191 / 404 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 21.15% |  |
| Net Profit YoY | 44.60% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |
| Revenue | 9192000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -59.49% | E |
| Profit Margin | -701.53% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | 21.15% | B |
| Net Profit YoY | 44.60% | B |
| Total Assets YoY | -40.90% | E |
| Net Assets YoY | -41.73% | E |
| Cash Flow Margin | -14.25% | D |
| OCF YoY | 21.15% | B |
| Turnover | 0.06 | E |
| Gearing Ratio | 26.20% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Kronos Bio",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "21.15%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "44.60%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "9192000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-59.49%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-701.53%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "21.15%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "44.60%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-40.90%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-41.73%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-14.25%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "21.15%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.06",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "26.20%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.83 | 227/404 | - | - | - |
| PB | 0.67 | 96/404 | 0.67 | 0.67 | 0.61 |
| PS (TTM) | 5.84 | 159/404 | 5.84 | 5.84 | 5.50 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (STOK.US) | A | A | B | A | B | A |
| 03 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 04 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.88 |
| Highest Target | 2.25 |
| Lowest Target | 2.25 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/KRON.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/KRON.US/norm.md)
- [Related News](https://longbridge.com/en/quote/KRON.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/KRON.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**